AlbuPure was derived from ProMetic’s Mimetic Ligand platform.
Novozymes and ProMetic Life Sciences will jointly promote the use of a new synthetic-ligand affinity adsorbent, marketed under the trade-name AlbuPure®, as a platform approach for the purification of albumin and albumin-fusion proteins. AlbuPure was designed for the development of Novozymes’ albufuse® albumin-fusion molecules.
ProMetic will be the exclusive manufacturer and supplier of the purification technology. Both parties will, however, retain ownership of their respective technologies. Additionally, both Novozymes and ProMetic will have the right to market AlbuPure.
AlbuPure was derived from ProMetic’s Mimetic Ligand™ technology and targeted at the capture and purification of recombinant albumin proteins produced in yeast. AlbuPure binds specifically to the albumin portion of the molecule and so can be used for the purification of any albufuse albumin-fusion protein.